Danaher Corporation $DHR Shares Sold by CMH Wealth Management LLC

Key Points

• CMH Wealth Management LLC reduced its stake in Danaher Corporation by 7.5% in the 2nd quarter, selling 3,098 shares and holding 38,463 shares valued at approximately $7.61 million.
• Danaher recently announced a quarterly dividend of $0.32 per share, with an ex-dividend date of September 26th, representing a yield of 0.7%.
• The stock is currently trading at around $193.31 and has received a consensus rating of "Moderate Buy" from analysts, with an average price target of $246.35.

CMH Wealth Management LLC lowered its position in shares of Danaher Corporation (NYSE:DHR - Free Report) by 7.5% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 38,463 shares of the conglomerate's stock after selling 3,098 shares during the period. Danaher comprises approximately 1.8% of CMH Wealth Management LLC's holdings, making the stock its 26th largest holding. CMH Wealth Management LLC's holdings in Danaher were worth $7,610,000 at the end of the most recent quarter.

Several other institutional investors have also recently made changes to their positions in DHR. Bank Pictet & Cie Europe AG grew its stake in Danaher by 22.8% in the fourth quarter. Bank Pictet & Cie Europe AG now owns 192,731 shares of the conglomerate's stock valued at $44,241,000 after purchasing an additional 35,730 shares during the last quarter. Worldquant Millennium Advisors LLC purchased a new position in Danaher in the fourth quarter valued at about $1,993,000. Voloridge Investment Management LLC purchased a new position in Danaher in the fourth quarter valued at about $3,763,000. Focus Partners Advisor Solutions LLC grew its stake in Danaher by 151.2% in the fourth quarter. Focus Partners Advisor Solutions LLC now owns 8,237 shares of the conglomerate's stock valued at $1,891,000 after purchasing an additional 4,958 shares during the last quarter. Finally, Vise Technologies Inc. grew its stake in Danaher by 110.9% in the fourth quarter. Vise Technologies Inc. now owns 6,671 shares of the conglomerate's stock valued at $1,531,000 after purchasing an additional 3,508 shares during the last quarter. Hedge funds and other institutional investors own 79.05% of the company's stock.

Wall Street Analyst Weigh In

DHR has been the topic of several analyst reports. Bank of America cut their target price on Danaher from $230.00 to $220.00 and set a "buy" rating on the stock in a research note on Monday. Deutsche Bank Aktiengesellschaft dropped their price target on Danaher from $240.00 to $235.00 in a research note on Thursday, June 5th. UBS Group dropped their price target on Danaher from $240.00 to $225.00 and set a "buy" rating on the stock in a research note on Wednesday, July 23rd. Wells Fargo & Company dropped their price target on Danaher from $210.00 to $205.00 and set an "equal weight" rating on the stock in a research note on Wednesday, July 23rd. Finally, Evercore ISI dropped their price target on Danaher from $230.00 to $226.00 and set an "outperform" rating on the stock in a research note on Tuesday, July 8th. Seventeen research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average target price of $245.91.

Danaher Price Performance

Shares of Danaher stock traded down $1.09 on Tuesday, reaching $189.37. The company's stock had a trading volume of 1,621,906 shares, compared to its average volume of 4,130,367. The company has a market capitalization of $135.60 billion, a P/E ratio of 40.10, a PEG ratio of 2.70 and a beta of 0.75. Danaher Corporation has a 52-week low of $171.00 and a 52-week high of $279.90. The stock has a 50-day moving average price of $200.02 and a 200-day moving average price of $198.03. The company has a quick ratio of 1.22, a current ratio of 1.62 and a debt-to-equity ratio of 0.32.

Danaher (NYSE:DHR - Get Free Report) last posted its quarterly earnings data on Tuesday, July 22nd. The conglomerate reported $1.80 EPS for the quarter, beating analysts' consensus estimates of $1.64 by $0.16. The business had revenue of $5.94 billion during the quarter, compared to analysts' expectations of $5.83 billion. Danaher had a return on equity of 10.70% and a net margin of 14.21%.The business's revenue was up 3.4% compared to the same quarter last year. During the same period in the previous year, the business earned $1.72 earnings per share. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. Analysts expect that Danaher Corporation will post 7.63 EPS for the current year.

Danaher Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, October 31st. Investors of record on Friday, September 26th will be given a dividend of $0.32 per share. This represents a $1.28 annualized dividend and a dividend yield of 0.7%. The ex-dividend date is Friday, September 26th. Danaher's payout ratio is presently 27.23%.

Insider Activity at Danaher

In related news, Director Teri List sold 2,778 shares of the business's stock in a transaction that occurred on Friday, August 22nd. The stock was sold at an average price of $211.06, for a total transaction of $586,324.68. Following the completion of the sale, the director directly owned 20,751 shares in the company, valued at approximately $4,379,706.06. The trade was a 11.81% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 11.20% of the company's stock.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.